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Introduction
Early in the secretory pathway of eukaryotic cells, integral 
plasma membrane (PM) proteins are inserted into the lipid 
bilayer of the ER. The mechanisms enabling polytopic mem-
brane proteins, composed of multiple transmembrane segments 
(TMSs), to integrate and fold in the ER membrane are not well 
documented. It is known that hydrophobic amino acids within 
N-terminally localized TMSs are suffi  cient to target membrane 
proteins to the ER, where they interact with and enter a protein-
conducting channel, or translocon, with a hydrophilic core. The 
translocon is a highly conserved heterotrimeric integral mem-
brane complex, i.e., the Sec61 complex in eukaryotes and SecY 
complex in bacteria (Osborne et al., 2005).
The successful ability to crystallize membrane proteins 
has greatly enhanced the understanding of two basic processes 
associated with membrane protein biogenesis. First, the struc-
ture of the Methanococcus jannaschii SecY translocon has been 
elucidated (van den Berg et al., 2004), which revealed that the 
protein-conducting channel is contained within SecY, the larg-
est translocon subunit and the Sec61 homologue. Despite un-
resolved questions regarding the structure of an active Sec61/
SecY translocon in vivo (Alder and Johnson, 2004), the protein-
  conducting channel, although perhaps quite fl  exible, is too 
  small to accommodate multiple TMSs (Rapoport et al., 2004; 
Osborne et al., 2005). Second, the structures of bacterial PM 
transporters LacY and GlpT, each composed of 12 TMSs 
(Abramson et al., 2003; Huang et al., 2003), have clearly shown 
that interactions between TMSs within the lipid phase of the 
membrane are not limited to immediately fl  anking  TMSs. 
Consequently, to fold properly, N-terminally localized TMSs that 
partition into the membrane of partially translated proteins must 
await the insertion of C-terminal TMSs. Together, these ad-
vances are consistent with the idea that polytopic membrane 
protein biogenesis occurs essentially in two discrete stages, 
i.e., membrane insertion and folding (Popot and Engelman, 1990; 
Engelman et al., 2003; Bowie, 2005).
To bridge these stages, and to account for the fact that 
polytopic membrane proteins cannot fold in a strict cotrans-
lational manner, the existence of chaperone-like proteins has 
been postulated (Lecomte et al., 2003; Alder and Johnson, 2004; 
Rapoport et al., 2004). The identifi  cation of membrane-localized 
chaperones in bacteria (Nagamori et al., 2004) and yeast 
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(Kota and Ljungdahl, 2005) provided strong support for this 
  notion. Consistent with the two-stage model of biogenesis, 
these chaperones do not appear to be necessary for the insertion 
of TMSs (Gilstring and Ljungdahl, 2000; Nagamori et al., 2004) 
but, nonetheless, they appear to interact early during the trans-
l  o  cation process to enable their substrate proteins to obtain native 
conformations (Nagamori et al., 2004; Kota and Ljungdahl, 2005). 
Although it remains to be determined, this novel class of chape-
rones may prevent TMSs of polytopic membrane proteins that 
do not normally interact in the mature protein from engaging in 
nonproductive interactions with fl  anking TMSs, or with other ER 
components, as they sequentially partition into the membrane.
In the yeast Saccharomyces cerevisiae, the recently charac-
terized membrane-localized chaperones exhibit a striking   degree 
of substrate specifi  city. The best studied of these chaperones, 
Shr3, is specifi  cally required for proper folding of amino acid 
permeases (AAPs; Kota and Ljungdahl, 2005). AAPs comprise 
a conserved family of 18 proteins with 12 TMSs (Gilstring and 
Ljungdahl, 2000). AAPs localize to the PM in an Shr3-dependent 
manner (Ljungdahl et al., 1992), where they function   to transport 
amino acids into cells. In the absence of Shr3 chaperone activity, 
AAPs aggregate, forming large molecular weight complexes 
(Kota and Ljungdahl, 2005), which are excluded from coatomer 
protein II transport vesicles (Kuehn et al., 1996, 1998). Conse-
quently, AAPs accumulate in the ER of shr3-null mutant strains. 
Shr3 has two well-defi  ned domains, a membrane domain com-
posed of four TMSs and a hydrophilic C-terminal domain. 
The chaperone activity of Shr3 is associated with the membrane 
  domain; the hydrophilic C-terminal domain is dispensable for 
function (Kota and Ljungdahl, 2005). The steady-state levels of 
AAPs are similar in both wild-type and shr3-null mutant cells 
( Ljungdahl et al., 1992; Gilstring et al., 1999; Kota and  Ljungdahl, 
2005). In wild-type cells, AAPs are degraded in the vacuole 
(  Roberg et al., 1997; Springael and André, 1998); the fate of 
 aggregated AAPs  in  shr3 mutants has not been investigated.
PM and secretory proteins are subject to ER quality-control 
systems that operate to ensure that only properly folded and 
assembled proteins exit the ER and enter into subsequent stages 
of the secretory pathway (Ellgaard et al., 1999). The ER lumen 
contains numerous factors that assist folding reactions (Nishikawa 
et al., 2005; Bukau et al., 2006). Terminally misfolded, or incom-
pletely assembled soluble or integral membrane proteins are 
degraded in a process referred to as ER-associated degradation 
(ERAD; Meusser et al., 2005). ERAD substrates are passed 
through or extracted from the membrane, ubiquitylated, and ul-
timately presented to cytoplasmic proteasomes for degradation. 
Several ERAD pathways have been defi  ned (Huyer et al., 2004; 
Vashist and Ng, 2004; Ravid et al., 2006). These pathways are 
composed of multimeric protein complexes organized around 
two membrane-localized E3 ubiquitin ligases, i.e., Doa10 and 
Hrd1 (Carvalho et al., 2006; Denic et al., 2006). These path-
ways appear to differentially recognize ERAD substrates, and 
thus far, all characterized ERAD substrates exhibit a strong 
  dependence on either Doa10 or Hrd1 pathways. With respect 
to polytopic membrane proteins, little is known regarding 
  how ERAD surveillance mechanisms differentiate between 
  proteins in the process of membrane insertion and folding 
from proteins that are terminally misfolded. The potential in-
volvement of membrane-localized chaperones in ERAD has not 
been examined.
We have investigated the chaperone activity of Shr3 from 
two perspectives. Using split Gap1 constructs, we examined 
the temporal requirement of Shr3 during membrane insertion 
and folding. Our results indicate that Shr3 interacts with an 
N-terminal fragment composed of TMSs I–V and maintains it 
in a conformation that enables it to functionally assemble with 
a coexpressed C-terminal fragment with TMSs VI–XII. Second, 
we assessed the potential role of Shr3 in quality-control mecha-
nisms that monitor AAP folding. We report that in the absence 
of Shr3, Gap1 aggregates are redundantly targeted to Doa10- 
and Hrd1-dependent ERAD pathways. Cells lacking these 
ERAD pathways exhibit restored amino acid uptake capacities. 
Thus, given suffi  cient time, AAPs are able to attain functional 
conformations independent of Shr3. These fi  ndings highlight 
the intimate link between folding and degradation during the 
biogenesis of polytopic membrane proteins.
Results
Shr3-dependent localization of Gap1
Previous studies examining the ER retention of AAP in shr3 
mutants have relied on microscopic evaluation (Ljungdahl et al., 
1992; Kota and Ljungdahl, 2005). The intracellular distribution 
of Gap1 in wild-type and shr3∆ mutant strains was examined 
by subcellular fractionation of whole cell lysates. In lysates 
from wild-type cells (Fig. 1, left) the majority of Gap1 cofrac-
tionated with the PM marker protein Pma1 (fractions 2 and 3) 
and the late Golgi marker Kex2 (peak fraction 6). The distribu-
tion of Gap1 was distinct from the ER marker Wbp1, which ex-
hibited the highest concentration in fraction 5. Gap1 migrated 
as two bands: a top band present in PM-containing fractions 
and a bottom band that was observed in fractions containing in-
ternal membranes. Gap1 is known to be posttranslationally modi-
fi  ed by phosphorylation, which correlates with increased amino 
acid uptake (Stanbrough and Magasanik, 1995). Also, phos-
phorylation is important for proper targeting of Gap1 from the 
Golgi to the PM and for preventing Gap1 down-regulation 
Figure 1.  Gap1 requires Shr3 for proper intracellular localization. Cell 
lysates prepared from SHR3 (PLY127) and shr3∆6 (FGY212) cells grown 
in SUD were fractionated on 12–60% step sucrose gradients. Proteins 
within fractions were separated by SDS-PAGE and analyzed by immuno-
blotting. The antibodies recognizing marker proteins Pma1 (100 kD), 
Wbp1 (49 kD), Kex2 (90 kD), and Dap2 (93 kD) were used to identify 
fractions containing PM, ER, Golgi, and vacuolar proteins, respectively. The 
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(De Craene  et al., 2001). The pattern of mobility we observed likely 
correlates with Gap1 becoming phosphorylated as it progresses 
through the secretory pathway on its way to the PM.
In lysates from shr3∆ cells (Fig. 1, left) the bulk of Gap1 
(bottom band form) cofractionated with the ER marker Wbp1 
(fractions 5 and 6), and there was minimal overlap with the Golgi 
marker Kex2 (peak fraction 7). Interestingly, a small amount 
of Gap1 (top band form) cofractionated with Pma1, the PM 
marker protein (fractions 2 and 3), suggesting that a portion of 
Gap1 is able to fold independently of Shr3. However, based on 
our extensive phenotypic analysis of shr3 mutants, including 
quantitative amino acid uptake assays, microscopic analysis 
(indirect immunofl  uorescence and Gap1-GFP), and biochemical 
approaches, the fraction of folded and correctly localized Gap1 
in  shr3 mutant cells is too low to confer detectable Gap1-
dependent phenotypes (Ljungdahl et al., 1992; Kuehn et al., 1996, 
1998; Gilstring et al., 1999; Kota and Ljungdahl, 2005). These 
results demonstrate that Shr3 is required to enable Gap1 to effi  -
ciently exit the ER and correctly localize to the PM.
Split Gap1 constructs insert 
into the membrane and assemble 
to gain functional conformations 
in an Shr3-dependent manner
In early studies regarding polytopic membrane protein biogenesis, 
it was found that truncated N- and C-terminal fragments of bacteri-
orhodopsin could incorporate into membranes and assemble to 
attain catalytic active conformations (Huang et al., 1981). Subse-
quent to this pioneering work, there have been numerous exam-
ples of functional “split” polytopic membrane proteins reported in 
the literature, including bacterial, yeast, and   mammalian proteins. 
To more fully understand the chaperone-dependent folding of 
AAPs, and to investigate the regions of Gap1 that require Shr3, 
we sought to take advantage of the possibility that Gap1 could be 
functionally expressed as a split protein.
The two-dimensional structure of Gap1 is depicted in 
Fig. 2 A. The N and C termini and even-numbered hydrophilic 
loops (L2–L10) are oriented toward the cytoplasm. The odd-
numbered loops (L1–L11) are luminally oriented during 
biogenesis and extracellular when Gap1 is correctly localized 
to the PM. With the exception of L5 (35 amino acids) and L7 
(22 amino acids), the odd-numbered loops are short and are 
composed of <10 amino acids. Consequently, the bulk of the 
non–membrane-associated amino acids are on the cytoplasmic 
side of the membrane.
We constructed alleles encoding two matched pairs of 
N- and C-terminal Gap1 fragments (Fig. 2 B). The fi  rst pair, 
encoded by the gap1 TM1-5 and gap1 TM6-12 alleles, expresses 
nonoverlapping Gap1 fragments truncated between TMS V 
and VI. The gap1 TM1-5 allele encodes an N-terminal Gap1 
fragment composed of the fi  rst 263 amino acid residues, and the 
gap1 TM6-12 allele encodes a C-terminal fragment of Gap1 
with a methionine residue placed immediately before residues 
264–602. The second pair, encoded by the gap1 TM1-6 and 
gap1 TM7-12 alleles, expresses partially overlapping Gap1 
fragments truncated between TMS VI and VII. The gap1 TM1-6 
encoded fragment is composed of the N-terminal 320 amino 
acid residues, and the gap1 TM7-12 allele has a methionine res-
idue placed before residues 311–602. Each of these alleles is 
expressed under control of the endogenous GAP1 promoter.
The truncated Gap1 alleles were separately introduced 
into the gap1∆-null mutant strain FGY15, and the growth of 
Figure 2.  Gap1 can be split into N- and 
C-terminal portions that assemble to form a func-
tional permease in an Shr3-dependent manner. 
(A) Schematic representation of the membrane 
topology of Gap1, which is composed of 602 
amino acid residues. The gray boxes depict 
the 12 membrane-spanning segments (I–XII); 
the numbers within boxes refer to the amino 
acid residues at the beginning and end of 
each membrane-spanning segment. The minus 
and plus symbols represent the positions of the 
charged amino acid residues in membrane-
spanning segments III, V, VI, VII, and XII. (B) Illus-
tration of full-length Gap1 and truncated gap1 
constructs. The gray boxes represent the 12 
transmembrane segments, the amino acid resi-
dues included in each fragment are indicated, 
and asterisks indicate the insertion of a methio-
nine residue to enable expression of C-terminal 
fragments. (C) Serial dilutions of cell sus-
pensions of strain FGY15 (gap1∆) carrying 
vector controls (VC; pRS316 and pRS317), 
or expressing full-length Gap1 (pPL247 and 
pRS317) or truncated gap1 constructs were 
prepared—gap1 TM1-5 (pJK97 and pRS317), 
gap1 TM1-6 (pJK96 and pRS317), gap1 TM6-
12 (pJK99 and pRS316), or gap1 TM7-12 
(pJK98 and pRS316), respectively. Aliquots of 
each dilution were applied to SAD or SAD supplemented with D-histidine (0.15%). (D) Serial dilutions of strain FGY15 (SHR3 gap1∆) or FGY135 (shr3∆ 
gap1∆) carrying vector controls or expressing full-length Gap1 or coexpressing matched pairs of truncated N- and C-terminal gap1 constructs gap1 TM1-5 
(pJK97) and gap1 TM6-12 (pJK99); gap1 TM1-6 (pJK96) and gap1 TM7-12 (pJK98); or gap1 TM1-5 (pJK97) and gap1 TM6-12MYC (pJK100), as indi-
cated, were applied to SAD or SAD with D-histidine (0.15%). Plates were incubated at 30°C for 2.5 d and photographed.JCB • VOLUME 176 • NUMBER 5 • 2007  620
transformants was assessed to determine whether the individ-
ually   expressed N- and C-terminal fragments exhibited Gap1 
transport activity (Fig. 2 C). Gap1 mediates the uptake of toxic 
d-amino acids (Regenberg and Hansen, 2000); consequently, 
cells lacking Gap1 activity are able to grow in media containing 
d-histidine (dilution series 1), whereas cells expressing functional 
full-length Gap1 cannot (dilution series 2). As expected, cells 
expressing the truncated N- and C-terminal fragments of Gap1 
grew (dilution series 3–6), indicating that the individually ex-
pressed truncated proteins are nonfunctional.
Next, plasmids encoding gap1 TM1-5 and gap1 TM6-12 
or gap1 TM1-6 and gap1 TM7-12 were introduced together as 
pairs into FGY15 (gap1∆). The growth of both strains carrying 
the matched pairs of N- and C-terminal fragments was inhibited 
by d-histidine (Fig. 2 D; dilution series 3 and 4). All strains grew 
well in the absence of d-histidine (Fig. 2 D, top); thus, the trivial 
explanation for the lack of growth, e.g., inhibitory secondary 
effects resulting from the expression of truncated Gap1 constructs, 
can be ruled out. These results demonstrate that in both instances, 
the truncated N- and C-terminal fragments assemble into an active 
split Gap1 that correctly localizes to the PM and facilitates 
d-histidine uptake. A slight difference in growth of the split Gap1 
expressing strains was noted; the growth of the split Gap1TM1-5/
TM6-12 expressing strain (dilution series 3) was nearly as poor as 
the strain expressing the intact full-length GAP1 allele (dilution 
series 2), whereas the growth of the split Gap1TM1-6/TM7-12 
expressing strain was better (dilution series 4). The noticeable 
difference suggests that split Gap1TM1-5/TM6-12 is more active.
To facilitate subsequent biochemical analysis of the 
C-terminal fragment, we inserted a thrice-reiterated myc epitope 
immediately preceding the stop codon of the gap1 TM6-12 allele. 
We examined the functionality of the C-terminal–tagged split 
gap1 TM6-12myc construct by coexpressing it with gap1 TM1-5 
in strain FGY15 (gap1∆). Growth of this strain (dilution 12) on 
media containing d-histidine was poor and similar to the un-
tagged Gap1TM1-5/TM6-12 expressing strain (dilution 11). 
Because growth was inhibited by d-histidine, the myc-tagged split 
Gap1 was able to assemble together with the N-terminal frag-
ment into an active Gap1.
Finally, we tested whether the untagged and tagged split 
Gap1 proteins require Shr3 for functional expression (Fig. 2 D; 
dilution series 5–8 and 13–16, respectively). The matched plas-
mid pairs were introduced into an shr3∆ gap1∆ strain (FGY135). 
Strain FGY135 is unable to take up d-histidine and grows well 
because of the lack of Shr3 (dilution series 5 and 13), even when 
full-length GAP1 is reintroduced on a plasmid (dilution series 
6 and 14). The transformants expressing either of the functional 
untagged and tagged split Gap1 proteins exhibited robust growth 
(dilution series 7–8 and 15–16, respectively). The strict require-
ment for Shr3 indicates that the split proteins, similar to full-
length Gap1, require the chaperone activity of Shr3 to attain 
functional conformations.
Shr3 prevents aggregation of split Gap1
To further investigate the role of Shr3 in Gap1 biogenesis, we 
examined whether split Gap1TM1-5/TM6-12 and Gap1TM1-5/
TM6-12myc aggregate in the absence of Shr3. Cell lysates 
from strains FGY15 (gap1∆) and FGY135 (shr3∆ gap1∆) ex-
pressing full-length Gap1, untagged split Gap1 TM1-5/TM6-
12, or tagged Gap1 TM1-5/TM6-12myc were solubilized in the 
presence of dodecyl-β-d-maltopyranoside (DM), and soluble 
proteins were separated by blue native PAGE (BN-PAGE; Fig. 
3). Consistent with our previous results (Kota and Ljungdahl, 
2005), monomeric full-length Gap1 was readily extracted from 
membranes prepared from SHR3 wild-type cells (Fig. 3 A, lanes 
1 and 3), but not from membranes prepared from shr3∆ cells 
(Fig. 3 A, lanes 2 and 4). In the absence of Shr3, Gap1 aggre-
gates form high molecular weight complexes that migrate as 
a diffuse smear. Similar results were obtained when we examined 
untagged split Gap1 (Fig. 3 B); monomers of the N-terminal 
fragment were readily extracted from membranes containing 
Shr3 (Fig. 3 B, lanes 1 and 3), whereas fewer monomers were 
extracted from membranes lacking Shr3 (Fig. 3 B, lanes 2 and 4). 
We were unable to detect intact assembled split Gap1 mono-
mers, indicating that DM extraction disrupts N- and C-terminal 
fragment association. The decreased effi  ciency to solubilize mono-
meric gap1 TM1-5 in shr3 mutant cells was not a consequence 
Figure 3.  Shr3 prevents aggregation of assembled split Gap1 constructs. 
Extracts from strains FGY15 (SHR3 gap1∆) and FGY135 (shr3∆ gap1∆) 
expressing full-length Gap1 (pPL247 and pRS317) (A), coexpressing gap1 
TM1-5 (pJK97) and gap1 6-12 (pJK99) (B), or coexpressing gap1 TM1-5 
(pJK97) and gap1 6-12myc (pJK100) (C and D) were prepared and solu-
bilized with DM at the indicated concentrations (μg DM μg
−1 protein). 
Solubilized proteins were separated by BN-PAGE on gradient gels and 
immunoblotted with anti–NT-Gap1 or c-myc antibodies as indicated. An 
aliquot of the extracts containing the truncated gap1 constructs (10 μg) 
was analyzed by SDS-PAGE and immunoblotted with anti–NT-Gap1 
(B and C, bottom) or with anti–c-myc antibody (D, bottom). The asterisks indi-
cate a nonspeciﬁ   c immunoreactive band unrelated to Gap1 that fortui-
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of reduced levels of gap1 TM1-5; both SHR3 and shr3∆strains 
expressed similar amounts of the N-terminal fragment (Fig. 
3 B, bottom).
Antibodies to native Gap1 recognize the N-terminal hy-
drophilic sequence preceding TMS I (anti-NT-Gap1; De Craene 
et al., 2001). To investigate the aggregation state of the C-terminal 
fragment, we coexpressed Gap1 TM1-5/TM6-12myc in SHR3 
and shr3∆ cells. In a manner entirely consistent with the un-
tagged split Gap1, the N-terminal fragment was readily ex-
tracted from membranes containing Shr3 (Fig. 3 C, lanes 1 and 3), 
and fewer monomers were extracted from membranes lacking 
Shr3 (Fig. 3 C, lanes 2 and 4). Next, we assessed whether mono-
mers of the C-terminal fragment could be extracted (Fig. 3 D). 
Similar to the N-terminal fragment, C-terminal monomers 
were more readily extracted from membranes with Shr3 (Fig. 3 D, 
lanes 1 and 3) compared with membranes lacking Shr3 (Fig. 3 D, 
lanes 2 and 4). However, the difference between gap1 TM6-12myc 
monomer levels in extracts from SHR3 and shr3∆cells was not 
as striking as for the N-terminal fragment. The SHR3 and shr3∆ 
strains expressed similar amounts of the N- and C-terminal 
fragments (Fig. 3, C and D, bottom). These results indicate that 
in the absence of Shr3, the N- and C-terminal fragments of split 
Gap1 are prone to aggregation.
Shr3 prevents aggregation of individually 
expressed N-terminal but not C-terminal 
split Gap1 fragments
To investigate the temporal requirement of Shr3 during the 
  assembly of split Gap, we examined the aggregation state of 
  individually expressed N- and C-terminal fragments. In cells 
expressing only the N-terminal fragment, gap1 TM1-5 mono-
mers were readily extracted from membranes with Shr3 (Fig. 4 A, 
lanes 1 and 3), but fewer monomers were extracted from mem-
branes lacking Shr3 (Fig. 4 A, lanes 2 and 4). These results, 
analogous to what we observe when membranes with coexpressed 
N- and C-terminal fragments are solubilized (Fig. 3), indicate 
that Shr3 interacts directly with the N-terminal fragment and 
prevents its aggregation.
In contrast to the N-terminal fragment, we were unable to 
fi  nd conditions to effi  ciently extract gap1 TM6-12myc mono-
mers from membranes in cells expressing only the C-terminal 
fragment (Fig. 4 B). Only small amounts of monomeric gap1 
TM6-12myc were extracted, and importantly, the presence 
(lanes 1 and 3) or absence (lanes 2 and 4) of Shr3 did not affect 
the levels of soluble C-terminal monomers. These results indi-
cate that in the absence of the fi  rst fi  ve N-terminal TMSs of 
Gap1, Shr3 is unable to associate with and prevent aggregation 
of C-terminal domain of Gap1 containing TMSs VI–XII. The 
clear Shr3 dependence of the N-terminal fragment is consistent 
with Shr3 interacting early during the biogenesis of Gap1, an 
interaction that is likely to occur before the partitioning of all 
12 TMSs into the lipid phase of the ER membrane.
Aggregated Gap1 is an ERAD substrate
The observed aggregation of full-length and truncated frag-
ments of Gap1 is the likely consequence of misfolding, which 
accounts for Gap1 retention and accumulation in the ER of 
shr3∆ mutants. Despite the accumulation of misfolded proteins, 
shr3∆ mutants do not exhibit an activated ER unfolded protein 
response (Gilstring et al., 1999). This may be explained by the 
fact that each of the TMSs of Gap1 are correctly inserted in the 
membrane independently of Shr3 (Gilstring and Ljungdahl, 
2000), and that the luminally exposed hydrophilic loops are 
rather short (Fig. 2 A). Thus, it is likely that Gap1 aggregates do 
not expose sequences that are recognized by Kar2, the luminal 
Hsp70 BiP homologue and key regulator of the unfolded pro-
tein response (Rutkowski and Kaufman, 2004). Prototrophic 
shr3∆ mutants grow as well as wild-type cells, even under 
conditions when AAP expression is induced (Ljungdahl et al., 
1992), suggesting that shr3 mutants are not negatively affected 
by the accumulation of AAP aggregates. To examine how shr3 
mutants cope with AAP aggregates, we examined the turnover 
of Gap1 using pulse-chase analysis (Fig. 5). Similar to previous 
reports (Roberg et al., 1997; Gilstring et al., 1999), the half-life 
of Gap1 in wild-type cells was  40 min (Fig. 5, A and C, solid 
circles). The half-life of Gap1 in shr3∆ mutants was similar to 
wild-type cells (Fig. 5, B and D, solid circles). Thus, despite the 
fact that Gap1 is differentially localized and present in different 
forms, i.e., PM and monomeric in SHR3 versus ER and aggre-
gated in shr3∆, Gap1 is effi  ciently degraded. The results sug-
gest that AAP aggregates are degraded by ERAD.
To test this possibility, we initially examined the degrada-
tion of Gap1 in pep4∆ mutants with an impaired capacity to de-
grade proteins in the vacuole (Jones et al., 1982). In SHR3 
wild-type cells, Gap1 degradation was markedly impaired (Fig. 
5 A, open squares), clearly demonstrating that in the presence 
of Shr3, Gap1 exits the ER and is degraded in the vacuole. This 
is consistent with the well-characterized traffi  cking pathways 
underlying the turnover of PM proteins (Haguenauer-Tsapis and 
André, 2004). In contrast, Gap1 was effi  ciently degraded in shr3∆ 
pep4∆ cells (Fig. 5 B, open squares), indicating that Gap1 
Figure 4.  Temporal requirement of Shr3 in the assembly of split Gap1. 
Extracts from strains FGY15 (SHR3 gap1∆) and FGY135 (shr3∆ gap1∆) 
expressing gap1 TM1-5 (pJK97 and pRS317) (A) or gap1 TM6-12myc 
(pJK100 and pRS316) (B) were prepared and solubilized with DM at the 
indicated concentrations (μg DM μg
−1 protein). Solubilized proteins were 
separated by BN-PAGE on gradient gels and immunoblotted with anti–NT-
Gap1 or c-myc antibodies as indicated. An aliquot of the extracts con-
taining the truncated gap1 constructs (10 μg) were analyzed by SDS-PAGE 
and immunoblotted with anti–NT-Gap1 (A; bottom) or with anti–c-myc anti-
body (B; bottom).JCB • VOLUME 176 • NUMBER 5 • 2007  622
aggregates are degraded independently of vacuolar hydrolases. 
This fi  nding is consistent with AAP aggregates being degraded 
by ERAD.
We examined this directly by constructing SHR3 and shr3∆ 
strains carrying single- and double-null alleles of the genes 
encoding ER-localized E2 ubiquitin-conjugating enzymes 
Ubc6 and Ubc7. Ubc6 and Ubc7 are required for ubiquity-
lating most characterized luminal and transmembrane ERAD 
substrates (Meusser et al., 2005). As expected, in SHR3 cells, 
the rate of Gap1 degradation was unaffected in ubc6∆, ubc7∆, 
or ubc6∆ ubc7∆ strains (Fig. 5 C). However, in strains lacking 
Shr3, the rate of Gap1 degradation was diminished in the pres-
ence of either ubc6∆ or ubc7∆ mutations (Fig. 5 D). In compar-
ison to ubc6∆, the ubc7∆ mutation exhibited a more pronounced 
stabilizing affect. Gap1 exhibited the greatest stability in the 
strain carrying both ubc6∆ ubc7∆ mutations. The clear depen-
dency on Ubc6 and Ubc7 demonstrates that aggregated Gap1 is 
an ERAD substrate.
Doa10- and Hrd1-dependent pathways 
redundantly target Gap1 for ERAD
Doa10- and Hrd1-dependent ERAD pathways are able to rec-
ognize and ubiquitylate membrane protein substrates. How-
ever, to date, all characterized ERAD substrates appear to be 
preferentially ubiquitylated by either Doa10- or Hrd1-dependent 
pathways. Thus, these E3 ligases appear to have distinct and 
nonredundant roles (Ismail and Ng, 2006). To determine which 
ligase is primarily responsible for ubiquitylating misfolded and 
aggregated Gap1, we constructed shr3∆ strains carrying 
doa10∆- or hrd1∆-null alleles. Unexpectedly, the stability of 
Gap1 increased only slightly and to the same extent in both of 
these strains (Fig. 6). These results suggested that both Doa10- 
and Hrd1-dependent pathways might function in a redundant 
manner to ubiquitylate Gap1 aggregates. This possibility was 
examined by following the degradation of Gap1 in an shr3∆ 
strain carrying both doa10∆- and hrd1∆-null alleles. In this 
strain, Gap1 was signifi  cantly stabilized, indicating that with 
respect to ubiquitylating Gap1 aggregates, Doa10 and Hrd1 are 
equally effective and, indeed, functionally redundant. Thus, 
multiple ERAD pathways are involved in the degradation of 
Gap1 aggregates.
Agp1 and Gap1 aggregates 
are degraded similarly
We sought to test whether our fi  ndings regarding the turnover of 
Gap1 can be applied to other AAPs and chose to investigate the 
turnover of Agp1 (Iraqui et al., 1999). We previously showed 
that Agp1 aggregates and is retained in the ER of cells lacking 
Shr3 (Kota and Ljungdahl, 2005). Using a simplifi  ed experi-
mental approach relying on cycloheximide, we found that, 
in wild-type cells, Agp1 is primarily degraded in the vacuole 
(Fig. 7 A); Agp1 was stabilized in a pep4∆ mutant, whereas deg-
radation was unaffected by the combination of ubc6∆ ubc7∆ 
mutations. In cells lacking Shr3, the stability of Agp1 was de-
pendent on ERAD (Fig. 7 B). In these cells, the turnover of 
Agp1 was largely Pep4 independent and, rather, was Ubc6 and 
Ubc7 dependent. As was found for Gap1, ubc7 mutations alone 
stabilized Agp1 aggregates almost as effi  ciently as ubc6 ubc7 
double mutations (not depicted). Also, both Doa10- and Hrd1-
dependent pathways redundantly targeted Agp1 for degrada-
tion; aggregates were degraded in doa10∆ and hrd1∆ single 
mutants with equal effi  ciency but were stable in doa10∆ hrd1∆ 
Figure 5.  Gap1 is degraded by ERAD in cells lacking SHR3. Pulse-chase 
analysis of Gap1 degradation in SHR3 (A and C) and shr3∆-null mutant 
cells (B and D). SAD-grown cells were labeled with [
35S]methionine for 
30 min and chased by the addition of excess unlabeled methionine and 
cysteine. Aliquots of cells were harvested at times indicated, and Gap1 
was immunoprecipitated from cell lysates (see Materials and methods). 
Immunoprecipitated proteins were separated by SDS-PAGE, and the amount 
of Gap1-associated radioactivity in samples was quantitated by phos-
phorimaging. The percentage of radioactivity remaining at each time point 
from at least two independent experiments is plotted. (A and B) Analysis of 
Pep4-dependent degradation. In A, solid circles indicate SHR3 (FGY127) 
and open squares indicate pep4∆ (FGY214). In B, solid circles indicate 
shr3∆ (FGY212) strains and open squares indicate shr3∆ pep4∆ 
(FGY219). (C and D) Analysis of the E2 ubiquitin ligase requirement. 
Strains in C are indicated as follows: solid circles, SHR3 (FGY127); open 
circles, ubc6∆ (FGY205); solid diamonds, ubc7∆ (FGY206); open squares, 
ubc6∆ ubc7∆ (JKY36). Strains in D are indicated as follows: solid circles, 
shr3∆ (FGY212); open circles, shr3∆ ubc6∆ (FGY209); solid diamonds, 
shr3∆ ubc7∆ (FGY210); open squares, shr3∆ ubc6∆ ubc7∆ (JKY37).
Figure 6.  Doa10- and Hrd1-dependent pathways redundantly target 
Gap1 aggregates for ERAD in shr3𝖫 mutant cells. Pulse-chase analysis of 
Gap1 degradation was performed as in Fig. 4. The percentage of Gap1 
remaining in each fraction from two or more independent experiments is 
plotted. The graph presents an analysis of Doa10- and Hrd1-dependent 
degradative pathways. Strains are indicated as follows: solid circles, 
shr3∆ (FGY212); open circles, shr3∆ doa10∆ (JKY29); solid diamonds, 
shr3∆ hrd1∆ (FGY257); open squares, shr3∆ hrd1∆ doa10∆ (JKY39).SHR3 AFFECTS AAP FOLDING AND DEGRADATION • KOTA ET AL. 623
double mutants. The data demonstrate that Agp1 aggregates are 
degraded in a manner identical to Gap1 aggregates.
Mutations that compromise ERAD partially 
suppress shr3-null mutant phenotypes
Little is known regarding surveillance mechanisms that monitor 
the folding of nonglycosylated polytopic membrane proteins, 
such as AAPs (Gilstring and Ljungdahl, 2000). Although as-
sumed to exist, mechanisms that distinguish between partially 
folded and misfolded states have not been identifi  ed, and the 
potential role of membrane-localized chaperones in such quality-
control mechanisms has not been examined. We suspected that 
the chaperone activity of Shr3 would have a critical role in 
discriminating between these two states and perhaps function to 
shield partially folded AAPs from being prematurely targeted 
for degradation by ERAD pathways. To evaluate this possibility, 
we monitored the growth of strains with impaired ERAD using 
two growth-based assays that provide an extremely sensitive 
measure of the activity and, hence, the folding state of three 
AAPs, i.e., Gap1 (Fig. 8 A) and Agp1 and Gnp1 (Fig. 8 B). We 
reasoned, based on our fi  nding that low levels of Gap1 can ap-
parently fold and exit the ER and reach the PM independently 
of Shr3 (Fig. 1 B), that if Shr3 normally prevents precocious 
degradation of AAPs, then mutations that impair ERAD would 
enable more AAPs to fold properly and lead to increased amino 
acid uptake.
Consistent with this notion, we observed that in comparison 
to shr3∆ mutants with intact ERAD pathways (Fig. 8; dilution 
series 2), shr3∆ strains carrying mutations that inactivate both 
Doa10- and Hrd1-dependent ERAD pathways display increased 
sensitivity to d-histidine and the toxic proline analogue azetidine-
2-carboxylate (AzC; Fig. 8; combinations of ubc6∆ ubc7∆ or 
doa10∆ hrd1∆; dilution series 5 and 8, respectively). As observed 
in our studies analyzing the degradation of Gap1 and Agp1 (Figs. 
6 and 7), we noted that strains carrying only the ubc7∆ mutation 
were almost as sensitive to amino acid analogues as the ubc6∆ 
ubc7∆ double mutant strains (Fig. 8; dilution series 4).
The data indicate that under conditions of impaired 
ERAD, cells have increased levels of properly folded and func-
tional AAPs in their PMs. We tested this possibility directly by 
examining the aggregation state of Gap1 in the ERAD-defective 
strains. Membranes from SHR3, shr3∆, shr3∆ ubc6∆ ubc7∆, 
and shr3∆ doa10 hrd1∆ strains were solubilized in the presence 
of DM, and soluble proteins were separated by BN-PAGE 
(Fig. 8 C). In comparison to membranes from the Shr3 wild-
type strain, we observed diminished levels of Gap1 monomers 
in membranes lacking Shr3 (Fig. 8 C, compare lanes 1 and 2). 
Substantially more (two- to threefold) Gap1 monomers were 
extracted from membranes prepared from shr3∆ strains carrying 
ubc6∆ ubc7∆ or doa10 hrd1∆ mutations (Fig. 8 C, compare 
lanes 3 and 4 with lane 2). The increased ability to solubilize 
Gap1 monomers accounts for the increased amino acid uptake 
in strains with impaired ERAD (Fig. 8, A and B). In summary, 
our data support the idea that in addition to facilitating folding 
of AAPs, Shr3 functions to shield partially folded AAPs from 
being prematurely targeted for degradation.
Discussion
Yeast possesses highly specialized ER membrane-localized 
chaperones (Kota and Ljungdahl, 2005). In this paper, we have 
Figure 7.  Agp1 is degraded similar to Gap1 in shr3𝖫 mutant cells. SHR3 
and shr3∆ strains carrying plasmid pJK60 (STP1∆131; Andréasson and 
Ljungdahl, 2002) to constitutively induce AGP1 expression were grown in 
SAD. Cycloheximide was added and lysates were prepared at the times 
indicated. Proteins, resolved by SDS-PAGE, were analyzed by immuno-
blotting using polyclonal rabbit anti-Agp1 (1:10,000). Immunoreactive 
bands were visualized using chemiluminescence detection reagents, and 
the chemiluminescent signals were quantitated. The percentage of Agp1 
remaining in each fraction from two or more independent experiments is 
plotted. (A) Analysis of Agp1 degradation in SHR3 cells. Solid circles, 
SHR3 (FGY127); open circles, pep4∆ (FGY214); open squares, ubc6∆ 
ubc7∆ (JKY36). (B) Analysis of Agp1 degradation in shr3∆ cells. Solid 
circles,  shr3∆ (FGY212); open circles, shr3∆ pep4∆ (FGY219); open 
squares,  shr3∆ ubc6∆ ubc7∆ (JKY37); solid diamonds, shr3∆ hrd1∆ 
doa10∆ (JKY39).
Figure 8.  Mutations that impair ERAD partially suppress shr3-null mutant 
phenotypes. (A) Growth characteristics of SHR3 (PLY127), shr3∆ (FGY212), 
shr3∆ ubc6∆ (FGY209), shr3∆ ubc7∆ (FGY210), shr3∆ ubc6∆ ubc7∆ 
(JKY37),  shr3∆ hrd1∆ (FGY257), shr3∆ doa10∆ (JKY29), and shr3∆ 
doa10 hrd1∆ (JKY39) strains. Cells were resuspended in water to an equal 
density and 10-fold dilutions were prepared. An aliquot from each dilution 
was applied to SD SAD containing and D-his (0.15%) to monitor Gap1 
activity. (B) Growth of the same strains as in A transformed with pJK60 
(STP1∆131) to constitutively induce SPS (Ssy1p-Ptr3p-Ssy5p) sensor–
regulated AGP1 and GNP1 expression (Andréasson and Ljungdahl, 2002). 
Aliquots of cell suspensions were applied to SD and SD containing AzC 
(SD + AzC) to monitor Agp1 and Gnp1 activity (Andréasson et al., 2004). 
The SD media contained leucine to induce SPS sensor–regulated AAPs. Plates 
were incubated at 30°C for 3 d and photographed. (C) Extracts from strain 
PLY127 (SHR3), FGY212 (shr3∆), JKY37 (shr3∆ ubc6∆ ubc7∆), and 
JKY39 (shr3∆ doa10 hrd1∆) grown in SAD were prepared and solubilized 
with DM (1.25 μg DM μg
−1 protein). Solubilized proteins were separated 
by BN-PAGE and immunoblotted with anti–NT-Gap1 antibody.JCB • VOLUME 176 • NUMBER 5 • 2007  624
experimentally addressed two questions regarding the chaper-
one activity of Shr3. First, is there a temporal requirement for 
the chaperone activity of Shr3 during the membrane insertion 
and folding of AAPs? Second, does the chaperone activity of 
Shr3 affect surveillance mechanisms that monitor the status of 
membrane protein folding? In answering these questions, we 
document that Shr3 has a central role in the biogenesis of AAPs, 
and our results illuminate the tight coupling between folding 
and quality-control mechanisms operating during biogenesis of 
polytopic membrane proteins.
We probed the temporal requirement of Shr3 during AAP 
folding by exploiting the fact that independently coexpressed 
truncated N- and C-terminal fragments of Gap1 can fold and 
assemble forming functional split Gap1 proteins (Fig. 2). Im-
portantly, the functional assembly of N- and C-terminal frag-
ments of Gap1 exhibited a strict dependence on Shr3. This 
fi  nding enabled us to directly analyze whether Shr3 maintains 
the N- and/or C-terminal fragments in productive assembly 
competent conformations. Consistent with our previous data re-
garding full-length Gap1 (Kota and Ljungdahl, 2005), we found 
that the N-terminal fragment exhibited an increased propensity 
to aggregate in membranes isolated from cells lacking Shr3, and 
importantly, its aggregation was not affected by the presence 
or absence of the C-terminal fragment (Fig. 3, B and C; and 
Fig. 4 A). In marked contrast, the ability to solubilize monomers 
of the C-terminal fragment exhibited not only a dependence on 
Shr3 (Fig. 3 D) but, more signifi  cantly, on the presence of the 
N-terminal fragment (Fig. 4 B). These data are consistent with 
a model in which Shr3 interacts early during the membrane in-
sertion of AAPs. Furthermore, as the N- and C-terminal frag-
ments are likely to individually insert into the membrane, Shr3 
is able to maintain the N-terminal fragment in a conformation 
that enables the C-terminal fragment to assemble with it. These 
observations raise many interesting questions regarding how 
these individual fragments, perhaps in analogy to subunits of 
multimeric membrane protein complexes, fi  nd each other before 
their functional assembly.
During translocation, exclusively hydrophobic TMSs rap-
idly partition into the lipid phase of the membrane (Heinrich 
et al., 2000). In contrast, less hydrophobic TMSs containing 
charged or polar residues partition into the membrane less readily 
and are retained in proximity to the translocon or to translocon-
associated proteins, e.g., TRAMs (Heinrich and Rapoport, 
2003). Recent results regarding the membrane insertion of 
aquaporin-4 are consistent with the view that individual TMSs 
exhibit distinct requirements during translocation (Sadlish et al., 
2005). After individually passing through a single entry site 
in Sec61, several TMSs of aquaporin-4 were found to interact 
with secondary peripheral sites on Sec61. These results suggest 
that the translocon may transiently retain certain TMSs to facili-
tate early folding events and to control their release into the 
membrane (Sadlish et al., 2005). The intrinsic chaperone-like 
activity of Sec61 translocon may thus suffi  ce to facilitate cor-
rect folding of many polytopic membrane proteins.
However, our results regarding membrane-localized 
chaperones indicate that complex, or larger, polytopic pro-
teins require the assistance of additional chaperones to fold. 
An appealing hypothesis, consistent with AAP aggregation ob-
served in the absence of Shr3, is that Shr3 facilitates the parti-
tioning of TMSs of AAPs containing charged or polar amino 
acid residues as they emerge from the translocon. According to 
this hypothesis, Shr3 may physically shield charged or polar 
residues within TMSs, enabling them to more rapidly partition 
into the membrane and fold, thereby preventing them from 
engaging in nonproductive interactions. Gap1 possesses fi  ve 
TMSs that have a single charged residue (Fig. 2 A). Although 
we have not systematically investigated the role of these charged 
residues, in several instances they are conserved, and mutations 
that exchange noncharged residues into their positions abolish 
catalytic activity (unpublished data). Consistently, a mutant 
Gap1 protein with a lysine replacing the conserved glutamate 
residue (E300) in TMS VI is inactive and retained in the ER 
(Lauwers and André, 2006).
In cells lacking Shr3, both Gap1 and Agp1 aggregates are 
effi  ciently recognized by ERAD surveillance systems that re-
dundantly activate Doa10- and Hrd1-dependent pathways (Figs. 
5, 6, and 7). In general, our results are consistent with the re-
cently proposed unifying concept for ERAD (Carvalho et al., 
2006). However, to our knowledge, AAP aggregates are the fi  rst 
substrates that target to both Doa10- (ERAD-C) and Hrd1- 
(ERAD-M/L) dependent pathways with equal effi  cacy. Our data 
indicate that these pathways function in parallel to degrade AAP 
aggregates. However, it is important to note that AAP aggre-
gates may in fact be composed of a nonhomogeneous mix of 
kinetically linked folding intermediates, which raises the possi-
bility that ERAD pathways preferentially degrade discrete 
folding intermediates. Previous reports regarding the organi-
zation of ERAD pathways suggested that membrane proteins 
with misfolded cytoplasmic domains are substrates of the Doa10 
pathway, whereas soluble secretory proteins and membrane 
proteins with misfolded luminal or membrane domains are sub-
strates of the Hrd1-dependent pathway (Huyer et al., 2004; 
Vashist and Ng, 2004; Ismail and Ng, 2006; Ravid et al., 2006). 
Although it remains to be determined, the involvement of the 
Doa10 pathway can be explained by the fact that the bulk of 
the non–membrane-associated amino acids of AAPs are on the 
cytoplasmic side of the membrane; presumably the folding 
of cytoplasmic domains are dependent on the proper folding of 
TMSs. With respect to the Hrd1 pathway, we suspect that in the 
absence of Shr3, misfolded TMSs of AAPs are recognized. 
Given the high level of sequence homology and dependence on 
Shr3, the other members of the AAP protein family are likely to 
be similarly degraded. Consequently, our fi  ndings substantially 
augment the number of known substrates of the Doa10- and 
Hrd1-dependent pathways.
We have found that AAPs can attain native structures, al-
beit ineffi  ciently, independent of the chaperone activity of Shr3 
(Figs. 1 and 8). Our fi  nding that mutations that impair ERAD 
enhance functional expression of AAPs highlights the intimate 
link between folding and degradation. There are two possible 
explanations for the ability of AAPs to fold independently of 
Shr3. First, a small portion of AAPs may fortuitously fold and 
attain native conformation as they insert in the membrane. In 
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substitute for the lack of Shr3, or the inherent chaperone-like 
functions associated with the Sec61 translocon may suffi  ce. 
Alternatively, AAP aggregates may not be solely composed of 
terminally misfolded proteins. This raises the possibility that 
low levels of aggregated AAPs are able to reenter a productive 
folding pathway. Because the topological orientation of each 
TMS of Gap1 is correctly fi  xed as they insert into the membrane 
(Gilstring and Ljungdahl, 2000), AAPs initiate folding at a point 
that is already quite constrained (Bowie, 2005). Thus, if provided 
suffi  cient time (e.g., in cells with impaired ERAD), aggregated 
AAPs may spontaneously rearrange from a kinetically trapped 
conformation into their native lower energy conformations.
The idea that Shr3 interacts with TMSs containing charged 
residues is consistent with it having a role in surveillance mech-
anisms that monitor folding. Previous work has demonstrated 
that charged residues within membrane-spanning segments pro-
vide key signals for targeting misfolded proteins for ERAD. In 
the case of unassembled α-subunits of the T cell receptor, which 
are retained and degraded in the ER, the degradation deter-
minant was mapped to two basic amino acid residues in the TMS 
(Bonifacino et al., 1990), and the placement of a single charged 
residue in a TMS of a cell surface protein caused it to be re-
tained and degraded in the ER (Bonifacino et al., 1991). Thus, 
by shielding charged amino acid residues, Shr3 not only facili-
tates folding but also prevents incompletely folded AAPs from 
being targeted for degradation. Furthermore, the fact that Shr3 
does not itself exit the ER (Kuehn et al., 1996), and newly 
  synthesized AAPs copurify with Shr3 (Gilstring et al., 1999), 
suggests that Shr3 retains actively folding AAPs in the ER. 
Thus, Shr3 may function analogously to the well-characterized 
N-linked glycosylation-based quality-control system, which pro-
vides temporal cues regarding folding of glycoproteins, preventing 
their premature exit out of the ER and targeting of folding inter-
mediates to ERAD (Helenius and Aebi, 2004).
Our fi  ndings underscore the importance of ER membrane-
localized chaperones in governing the stability of membrane 
proteins. In mammalian cells, insulin-induced gene (INSIG) pro-
teins appear to have chaperone-like activity that infl  uences the 
sterol-dependent degradation of 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG CoA) reductase and ER retention of Scap 
(for review see Goldstein et al., 2006). When sterol levels are 
high, INSIG proteins bind sterol-sensing membrane domains of 
HMG CoA reductase and Scap. As a consequence of binding, 
HMG CoA reductase is targeted to ERAD and Scap is prevented 
from exiting the ER, two events that lead to decreased choles-
terol biosynthesis and uptake. In yeast, the INSIG homologues 
Nsg1 and Nsg2 associate with HMG CoA reductase, facilitating 
the folding of the sterol-sensing membrane domain and inhibiting 
Hrd1-dependent degradation (Flury et al., 2005).
Finally, we note striking similarities between the ineffi  -
cient folding of AAPs in cells lacking Shr3 and the folding of 
the mammalian Cl
− channel cystic fi  brosis transmembrane con-
ductance regulator (CFTR). The folding of native CFTR is in-
effi  cient (Ward and Kopito, 1994): only 25% of synthesized 
CFTR folds properly, and the remaining 75% is degraded by 
multiple ERAD mechanisms (Younger et al., 2006). The similar-
ities to the situation in yeast suggest that CFTR folding occurs in 
the absence of dedicated Shr3-like chaperones; consequently, 
CFTR folding intermediates are more or less constitutively and 
prematurely targeted for degradation. The ability of small mole-
cules to act as chaperones, and the temperature-dependent char-
acteristics of CFTR folding supports this notion (Denning et al., 
1992; Brown et al., 1996; Loo et al., 2005). Also, the folding 
intermediate that accumulates as a result of the disease-causing 
∆F508 mutation is kinetically trapped. Interactions with Hsp90, 
which are positively and negatively modulated by cochaperones, 
determine the fate of this misfolded intermediate (Wang et al., 
2006). The down-regulation of cochaperone Aha1 enables ∆F508 
CFTR to fold, exit the ER, and become functionally expressed 
in the PM. Presumably, reduced levels of Aha1 circumvent sur-
veillance mechanisms that normally target ∆F508 CFTR for 
ERAD. It will be interesting to continue to exploit the yeast 
system described here to dissect out further mechanistic details 
regarding the quality-control surveillance systems that monitor 
the folding of polytopic membrane proteins.
Materials and methods
Strains, plasmids, and media
Yeast strains and plasmids are listed in Table I. FGY206 was created by 
transforming PLY123 with a PstI–BamHI DNA fragment containing ubc7∆::
LEU2 from pGR172 (Vassal et al., 1992). FGY205 was created by trans-
forming PLY123 with a HindIII–HindIII DNA fragment containing ubc6∆::
LEU2 from pTX33 (Sommer and Jentsch, 1993). PLY127 was transformed 
with a EcoRI–XhoI DNA fragment containing pep4∆::hisG-URA3-neo-hisG 
from pAS173 (provided by A. Sachs, University of California, Berkeley, 
Berkeley, CA), and a Ura
+ transformant was propagated on medium con-
taining 5-ﬂ  uoroorotic acid (FOA), resulting in the unmarked pep4∆::hisG 
strain FGY217. PLY127, FGY205, FGY206, and FGY217 were trans-
formed with a linear EcoRI–SalI DNA fragment containing shr3∆5::hisG-
URA3-neo-hisG from pPL288 (Kuehn et al., 1996); Ura
+ transformants 
were propagated on FOA-containing medium; and strains FGY212, 
FGY209, FGY210, and FGY219, each carrying the unmarked shr3∆6 de-
letion, were obtained. FGY257 was constructed by transforming FGY212 
with a SphI–SalI DNA fragment containing hrd1::URA3 (Bays et al., 
2001). Strains JKY29 and JKY39 were constructed by deleting the entire 
sequence of DOA10 in FGY212 and FGY257 with a PCR-ampliﬁ  ed 
natMX4 cassette (primers F-doa10D and R-doa10D). JKY36 and JKY37 
were constructed from FGY205 and FGY209 by deleting the coding se-
quence of UBC7 with a PCR-ampliﬁ  ed natMX4 cassette (primers F-ubc7D 
and R-ubc7D).
Plasmid pJK92 was created by inserting a 3.4-kb SalI–NotI frag-
ment encoding Gap1 from pPL247 into SalI–NotI–restricted pRS317 
(Sikorski and Boeke, 1991). Plasmids expressing split Gap1 constructs 
under the control of the endogenous GAP1 promoter were created by 
homologous recombination in yeast. Plasmids pJK97 (gap1 TM1-5) and 
pJK96 (gap1 TM1-6) expressing N-terminal fragments of Gap1 were cre-
ated by introducing Bsu36I–BglII–restricted pPL247 together with primer 
pairs F:1-5TM/R:1-5TM and F:1-6TM/R:1-6TM, respectively. Plasmids 
pJK98 (gap1 TM7-12) and pJK99 (gap1 TM6-12) expressing C-terminal 
fragments of Gap1 were created by cotransforming BsiWI–BsaBI re-
stricted pJK92 with primer pairs F:7-12TM/R:7-12TM and F:6-12TM/
R:6-12 TM, respectively. A thrice-reiterated myc epitope was inserted at 
the C terminus, immediately before the stop codon, creating plasmid 
pJK100; 3×myc was PCR ampliﬁ   ed from plasmid pPL329 (primers 
F-Gap1TM6-12–3×MYC/R-Gap1TM6-12–3×MYC) and cotransformed 
together with SphI–SalI–restricted pJK99.
Standard media, YPD (yeast extract, peptone, dextrose) and SD 
(synthetic complete), were prepared as described previously (Burke et al., 
2000). Ammonium-based synthetic complex (Andréasson and Ljungdahl, 
2002) and minimal media containing urea (SUD), proline (SPD), and 
allantoin (SAD) as the sole nitrogen source were prepared as described 
previously (Ljungdahl et al., 1992; Kota and Ljungdahl, 2005). Minimal 
media were supplemented as required. Media were made solid with 2% 
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Subcellular fractionation and immunoblot analysis
Cells were grown overnight in SD to an OD600 of 2–3, harvested, washed 
once in water, and resuspended in SUD to a starting OD600 of 0.1. Cells 
were grown at 30°C and harvested when cultures reached an OD600 of 
0.8, and protein extracts were prepared and fractionated on 12–60% 
sucrose gradients essentially as described previously (Egner et al., 1995). 
1-ml fractions were collected from the bottom of the gradients using a Fraction 
Recovery System (Beckman Coulter). Fractions 1 and 2 and 10 and 11 were 
separately pooled, and proteins from equal aliquots of the nine resulting 
fractions were concentrated by TCA precipitation. Proteins were separated 
by SDS-PAGE and blotted onto nitrocellulose membranes.
Immunoblots were incubated as indicated with primary antibody 
(rabbit polyclonal) in blocking buffer (phosphate-buffered saline and 0.1% 
Tween 20) diluted as follows: α-Agp1p, 1:10,000; α-Dap2, 1:2,000; 
α-Gap1, 1:20,000; α-Kex2, 1:1,000; α-Pma1, 1:3,000; α-Shr3p, 1:1,000; 
α-Wbp1, 1:1,000. Blots were washed three times for 15 min with wash 
buffer (blocking buffer plus 5% milk) and incubated with horseradish 
peroxidase–coupled secondary antibody, donkey α-rabbit Ig (GE Healthcare), 
diluted 1:5,000 in wash buffer. Blots were washed three times for 15 min 
with wash buffer, and immunoreactive proteins were visualized by chemi-
luminescence detection reagents (ECL-PLUS Western Blotting Detection 
System; GE Healthcare) and the LAS1000 camera system (Fuji). The α-Gap1 
and  α-Agp1 antisera were provided by B. André (Universite Libre de 
Bruxelles, Brussels, Belgium). The α-Pma1, α-Wbp1, and α-Kex2 antibodies 
were obtained from C. Slayman (Yale University, New Haven, CT), 
S. te Heesen (Swiss Federal Institute of Technology, Zürich, Switzerland), and 
R. Fuller (University of Michigan, Ann Arbor, MIC), respectively.
Pulse-chase analysis
Radiolabeling and immunoprecipitations were conducted essentially as 
described previously (Silve et al., 1991; Volland et al., 1994). In brief, 
cells grown in SAD (plus uracil) to an OD600 of 0.5–0.8 were used to inocu-
late fresh SAD (plus uracil) at an OD600 of 3. Cultures were incubated for 
30 min before the addition of 
35S-methionine (25 μCi/OD600 cells; GE 
Healthcare). Cells were labeled for 30 min, after which an aliquot of 
100× chase solution (25 mM L-methionine and 25 mM L-cysteine) was 
added. At the times indicated, 1-ml aliquots of culture were placed in 
Eppendorf tubes containing 60 μl ice-cold lysis solution (1.85 M NaOH and 
7% β-mercaptoethanol), rapidly mixed by rigorous vortexing, and after 
a 10-min incubation on ice, 60 μl of 50% TCA was added. Precipitated 
proteins, pelleted by centrifugation for 15 min at 12,000 g, were washed 
once in 60 μl of 1 M Tris, pH 7.5, and solubilized in 0.5% SDS for 10 min 
at 37°C. Proteins were diluted with TNET buffer (1% Triton X-100, 50 mM 
Tris, pH 7.4, 150 mM NaCl, and 5 mM EDTA) to a ﬁ  nal volume of 0.6 ml. 
Insoluble material was removed by centrifugation for 30 min at 12,000 g. 
Rabbit anti-Gap1 antibodies were added (1:1,500), and samples, continu-
ously mixed by inversion, were incubated overnight at 4°C. 40 μl of a 
12.5% (vol/vol) suspension of protein A–Sepharose CL-4B beads (GE 
Healthcare) was added to each sample, and incubations were continued 
for 3 h at 4°C. Immunoprecipitated material was collected by centrifuga-
tion and washed three times with TNET buffer and once with TNET without 
Triton X-100. Precipitated proteins were eluted by incubation for 10 min at 
39°C in 2× SDS-PAGE sample buffer. Eluted proteins were separated by 
SDS-PAGE in a 10% gel. Gels were ﬁ  xed in glacial acetic acid/methanol/
H2O (10:20:70), rinsed brieﬂ  y in water, and dried. Radiolabeled proteins 
were detected and quantiﬁ  ed by phosphorimaging (Fujix Bio-Image Ana-
lyzer BAS1500; Fuji).
Evaluation of protein stability in the presence of cycloheximide
Cultures grown at 23°C in SAD (plus uracil) to an OD600 of 0.8–1 were 
treated with 400 μg/ml cycloheximide. At the times indicated, 1-ml ali-
quots were removed to Eppendorf tubes containing 250 μl ice-cold lysis 
solution (1.85 M NaOH), rapidly mixing by rigorous vortexing, and after 
a 10-min incubation on ice, 250 μl of 50% TCA was added. Precipitated 
proteins, pelleted by centrifugation for 15 min at 12,000 g, were washed 
once in 100 μl of 1 M Tris, pH 7.5, and solubilized in 2× SDS-PAGE 
sample buffer. Proteins were resolved by SDS-PAGE and analyzed by 
immunoblotting.
BN-PAGE
BN gels and whole cell protein extracts were prepared as previously de-
scribed (Kota and Ljungdahl, 2005). Protein extracts from cells grown in 
SAD at 25°C were solubilized at 4°C for 35 min in the presence of DM at 
the concentrations indicated. Extracts containing full-length Gap1 and split 
Gap1 fragments were separated using 4–15% and 4–20% gradient gels, 
respectively. High molecular weight marker proteins (GE Healthcare) were 
used as standards.
Members of Ljungdahl laboratory are acknowledged for constructive 
comments. We are indebted to Bruno André for his generous gifts of α-Gap1 
Table I. S. cerevisiae strains and plasmids
Strain or plasmid Genotype/description Source or reference
PLY123 MATα ura3-52 lys2∆201 leu2-3,112 Ljungdahl laboratory
PLY127 MATα ura3-52 lys2∆201 Ljungdahl laboratory
FGY212 MATα ura3-52 lys2∆201 shr3∆6 This work
FGY206 MATα ura3-52 lys2∆201 leu2-3,112 ubc7::LEU2 This work
FGY210 MATα ura3-52 lys2∆201 leu2-3,112 ubc7::LEU2 shr3∆6 This work
FGY205 MATα ura3-52 lys2∆201 leu2-3,112 ubc6::LEU2 This work
FGY209 MATα ura3-52 lys2∆201 leu2-3,112 ubc6::LEU2 shr3∆6 This work
FGY217 MATα ura3-52 lys2∆201 pep4∆ This work
FGY219 MATα ura3-52 lys2∆201 pep4∆shr3∆6 This work
FGY257 MATα ura3-52 lys2∆201 shr3∆6 hrd1∆::URA3 This work
JKY29 MATα ura3-52 lys2∆201 shr3∆6 doa10∆::natMX4 This work
JKY36 MATα ura3-52 lys2∆201 leu2-3,112 ubc6∆::LEU2 ubc7∆::natMX4 This work
JKY37 MATα ura3-52 lys2∆201 leu2-3,112 shr3∆6 ubc6∆::LEU2 ubc7∆::natMX4  This work
JKY39 MATα ura3-52 lys2∆201 shr3∆6 hrd1::URA3 doa10∆::natMX4 This work
FGY15 MATa ura3-52 lys2∆201 leu2-3,112 gap1∆2::LEU2 Gilstring and Ljungdahl, 2000
FGY135 MATa ura3-52 lys2∆201 leu2-3,112 gap1∆2::LEU2 shr3∆6 Gilstring and Ljungdahl, 2000
pPL247 GAP1 in pRS316 (URA3)  Ljungdahl et al., 1992
pJK92 GAP1 in pRS317 (LYS2) This work
pJK96 GAP1 TM1-6 in pPL247 This work
pJK97 GAP1 TM1-5 in pPL247 This work
pJK98 GAP1 TM7-12 in pJK92 This work
pJK99 GAP1 TM6-12 in pJK92 This work
pJK100 GAP1 TM6-12-3xMyc in pJK92 This work
PJK60 STP1∆131 in pRS317 Kota and Ljungdahl, 2005SHR3 AFFECTS AAP FOLDING AND DEGRADATION • KOTA ET AL. 627
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Robert Fuller for α-Pma1, α-Wbp1, and α-Kex2 antibodies, respectively.
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